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Background: 4CMenB is immunogenic in infants and toddlers. We assessed persistence of human com-
plement serum bactericidal activity (hSBA) following a fourth dose administered at 12, 18 or 24 months
and characterised the antibody response to a fifth dose administered at 4 years of age.
Methods: A phase 3, open label, multi-centre extension to a randomised controlled trial conducted in four
countries (number of centres): Czech Republic (nineteen), Italy (four), Spain (four) and the United
Kingdom (four). Four-year-old children who were either 4CMenB-naïve or had previously received a vari-
ety of 3-dose infant priming schedules and a booster vaccine as toddlers (follow-on group) were
recruited. Venous blood samples were obtained to determine hSBA against four reference strains; acting
as targets to assess immunity to each of the vaccine antigens, NadA (5/99), fHbp (H44/76), PorA
(NZ98/254), and NHBA (M10713) at baseline (prior to vaccination, all participants) and one month fol-
lowing a dose of 4CMenB for all vaccine-naïve and follow-on participants primed with the 2, 3, 4 sched-
ule, and a third of follow-on participants primed with a 2, 4, 6 month schedule.
Results: At baseline (prior to vaccination), the proportion of participants (n = 468) with hSBA titersP 5
was similar across all followon groups: 89–100% against 5/99; 12–35% for H44/76; 8–12% for
NZ98/254 and 53–80% for M10713 compared with 5%, 0%, 0%; and 60% respectively, for the vaccine-
naïve controls (n = 206). Following a dose of 4CMenB at 4 years of age, this increased to 100% (5/99),
97–100% (H44/76), 80–95 % (NZ98/254) and 84–100% (M10713) (n = 210), compared with 89%, 70%,
24%, and 76% respectively for vaccine-naïve controls (n = 192).
Conclusion: Waning of protective antibodies occurred 12–36 months after toddler booster regardless of
age at boost. This was least marked against target strains 5/99 and M10713. A robust memory response
occurred after a booster dose given at 4 years of age.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The licensed four-component capsular group B meningococcal
vaccine (4CMenB) was introduced into the UK routine infant
immunisation programme in September 2015 [1]. Demonstration
396 M.A. Iro et al. / Vaccine 35 (2017) 395–402of immunogenicity of this vaccine in a range of infant and toddler
immunisation schedules is important to establish its potential in
the varied international vaccine programmes. Whilst antibody
responses and persistence following different vaccination sched-
ules in infancy [2] and toddler years [3–5] have been described,
data on the impact of the previously received vaccination schedule
on long term bactericidal antibody persistence and by extrapola-
tion, protection against disease, are few.
In this study we assessed persistence of bactericidal antibodies
to 4 years following a fourth dose of 4CMenB given at either 12, 18
or 24 months of age to participants who had received different
4CMenB priming schedules in infancy. In addition, we investigated
the antibody response and reactogenicity following a fifth dose of
4CMenB given at 4 years of age.2. Methods
2.1. Study design
A Phase 3, open label, multi-centre extension to a randomised
controlled trial conducted (November 2012 to October 2013) in
Czech Republic, Italy, Spain, and the United Kingdom (nineteen,
four, four, four centres respectively). Recruitment in the UK was
via mail out of information letters through the National Health Ser-
vice child health computer databases. In other centres, this was
through paediatric hospitals or private practices. This study was
conducted in accordance with the provisions of the Declaration
of Helsinki (1996) and the International Conference on Harmoniza-
tion Guidelines for Good Clinical Practice and appropriate regula-
tory approval was obtained from relevant authorities in each
participating country prior to recruitment.
2.2. Study objectives
The primary objective was to explore antibody persistence to 4
years of age after a fourth dose of 4CMenB administered in toddler
years. Secondary objectives included characterisation of antibody
response to, and tolerability of a fifth dose of 4CMenB.
2.3. Participant selection and randomisation
In the original infant study [2], participants were randomised
(2:2:1:1) to receive 4CMenB either at (a) 2, 4, 6 months of age with
routine immunisation (246Con), (b) 2, 4, 6 months of age, with rou-
tine vaccines at 3, 5, 7 months of age (246Int), or (c) 2, 3, 4 months
concomitant with routine vaccines (234Con), while a fourth group
of infants received routine vaccines alone (Control). In the first
extension study [5], previously immunised participants were ran-
domised (1:1:1) to receive a fourth dose at 12, 18 or 24 months
of age. In addition, follow-on participants from the Control group
of the original infant study as well two new Control groups of
4CMenB-naive participants received two catch-up doses at 12
and 14, 18 and 20, and 24 and 26 months.
Healthy 4-year-old children who completed the vaccination
course in the first extension study were invited to participate in
this study. Inclusion and exclusion criteria are shown in Table 1
Supplementary file.
Groups 246Con and 246Int participants were randomised in a
2:1 ratio to a non-vaccination subset (subset#1) and a vaccination
subset (subset#2) using a randomisation list produced by a vali-
dated system used by the Novartis Vaccine Diagnostics. The ran-
domisation sequence within each group was executed with a
permuted block size of 3. Allocation until the point of enrolment
was masked from parents of participants through the use of sealed
opaque envelopes. Group allocation was not masked from studystaff and parents of participants after enrolment, but the label code
ensured blinding of the laboratory personnel.
Participants assigned to subset #1 were evaluated for antibody
persistence alone. Participants assigned to subset #2 and all partic-
ipants from Group 234Con received a fifth dose of 4CMenB and
were evaluated for both persistence and antibody response. An
additional group of healthy 4CMenB-naïve 4-year-old children
were recruited to act as a comparison group for antibody persis-
tence and response to single dose of 4CMenB. All ‘control’ follow-
on participants from the two previous studies received a third dose
of 4CMenB and were also evaluated for both persistence and anti-
body response. Data from this cohort are presented elsewhere [6].
2.4. Study vaccine
4CMenB consisted of 50 lg each of Neisserial adhesin A (NadA),
and fusion proteins containing Neisseria heparin binding antigen
(NHBA) and Factor H binding protein (fHbp), 25 lg detoxified
OMV from N. meningitidis strain NZ98/254, 1.5 mg aluminium
hydroxide and 10 mM histidine in 0.5 ml water for injection (Lot
number 112801). This was administered by intramuscular injec-
tion into the deltoid muscle of the non-dominant arm, using a
23G needle.
2.5. Immunogenicity evaluation
Venous blood samples were collected at baseline (prior to vac-
cination) and 30 (4/+10) days after each 4CMenB dose to deter-
mine hSBA against three chosen target strains selected to broadly
determine responses to the individual target strains: 5/99 (NadA),
44/76-SL (fHbp), and NZ98/254 (OMV).
As previously described [7], an additional strain M10713 was
included post hoc and assessed to determine SBA response against
NHBA. hSBA was expressed as interpolated titers according to
reciprocal serum dilutions yielding 50% or greater killing of the tar-
get strain after 60 min of incubation compared with growth at time
0. An interpolated titreP 5 represented 95% confidence that par-
ticipants achieving this titre had a protective hSBA (P1: 4) [8].
The Novartis Vaccines Clinical Sciences Laboratory, Marburg, Ger-
many performed the serological analysis.
2.6. Reactogenicity evaluation
All participants were observed for approximately 30 min after
each vaccination for any reactions. Parents recorded and graded
both local injection site and systemic reactions (Table 2, Supple-
mentary File) for seven days following vaccination. Safety follow-
up was completed 6 months after the last dose of 4CMenB. All seri-
ous adverse events (SAEs) reported during the study were
recorded; the relationship between adverse events and the study
vaccine was determined by a study investigator.
2.7. Statistical analysis
The pre-specified analysis population for immunogenicity was
the Full analysis set (FAS) population, consisting all participants
who provided at least one evaluable serum sample either at base-
line (Persistency immunogenicity population) or after receipt of
4CMenB (Immunogenicity population). Antibody persistence was
determined by calculating, for each of four indicator strains, the
percentage of participants with hSBA titresP 5 at baseline and
associated two-sided 95% Clopper-Pearson confidence intervals
(CIs). In addition, hSBA titers were log transformed and their geo-
metric mean titers (GMTs), and associated 2-sided 95% CI were
computed per study group and per strain using two-way analysis
of variance with factors for vaccine group and country. Safety
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group reporting local and systemic adverse events (AEs) and/or
SAEs after vaccination. All participants who received at least one
immunisation and provided some safety data were included in
safety analyses. Safety results are reported descriptively.
The sample size for the follow-on groups was determined using
the number of participants in the first extension study who were
eligible to participate in this study. For the 4CMenB-naïve group,
190 participants were needed to detect an underlying percentage
immune response rate of 80% for reference strains 44/76-SL,
5/99, NZ98/254 with 80% power, assuming a 15% dropout rate. Sta-
tistical analysis was performed using SAS version 9.1 and indepen-
dent validation of the analysis using SAS version 9.3(SAS Institute,
Cary, NC).
3. Results
Participant disposition is shown in Fig. 1. A total of 682 partic-
ipants [non-vaccination group = 242; booster vaccination
group = 231; vaccine-naïve controls = 209] were enrolled from
the four countries [Italy: 140 (20.5%), Czech Republic: 187
(27.4%)], [Spain: 87 (12.8%), United Kingdom: 268 (39.3%)]. There
were 355 (52%) male and 327 (48%) female participants. The med-
ian age at the time of enrollment was 51 months (range
48–59 months). The most common self-defined ethnicity was
white (97%). Baseline demographic data are summarised in Table 1.
3.1. Antibody persistence to 4 years of age
The proportions of participants with hSBAP 5 for the different
target strains are shown in Table 2; Fig. 1 Supplementary file.
Against all target strains and across all study groups, the GMTs at
baseline were lower than those at one month after the last vaccina-
tion in the first extension study (Table 3, Fig. 2). They were how-
ever higher in the follow-on than the vaccine-naïve group
(respectively) for 5/99 (36–111 vs. 1.16) but less so for 44/76-SLAge at Dose 4  
(N enrolled) 
4CMenB 
Vaccinated 
Safety 
246Con 
12 months 
(N=67) 
18 months 
(N=61) 
24 months 
(N=60) 
No (N=38) 
Yes (N=29) 
No (N=41) 
Yes (N=20) 
No (N=43) 
Yes (N=18) 
N=38 
N=29 
N=41 
N=20 
N=43 
N=17 
246Int 
12 months 
(N=66) 
18 months 
(N=64) 
24 months 
(N=55) 
No (N=47) 
Yes (N=19) 
No (N=36) 
Yes (N=27) [d.=1] 
No (N=37) 
Yes (N=17) 
N=47 
N=19 
N=36 
N=27 
N=37 
N=17 [c.=1] 
234Con 
12 months 
(N=43) 
18 months 
(N=29) 
24 months 
(N=28) 
No (N=0) 
Yes (N=43) 
No (N=0) 
Yes (N=29) 
No (N=0) 
Yes (N=28) 
N=43 
N=29 
N=28 
No (N=0) 
Yes(N=207)[d.=2] 
Naive 
N=206 
(N=209) 
Fig. 1. Study flo(1.51–2.69 vs. 1.04) and NZ98/254 (1.25–1.62 vs. 1.01). For
M10713, GMTs were relatively high both in the follow-on and
vaccine-naïve groups, with no apparent differences seen (Table 3).
3.2. Antibody response to vaccination at 4 years of age
The proportions of participants with hSBA titresP 5 for each
target strain are shown in Table 2 and Fig. 1 Supplementary File.
These were similar across all follow-on groups, being 100% for
5/99; 97–100% for 44/76-SL); 80–95% for NZ98/254 and 84–100%
for M10713 and were generally lower in the naïve control group
(89%, 70%, 24%, and 76% respectively). Against three of the four tar-
get strains (5/99, 44/76-SL, NZ98/254), hSBA GMTs were higher in
the follow-on groups than the vaccine-naïve controls (Table 3,
Fig. 2) but were similar for the follow-on and vaccine-naïve con-
trols for NHBA.
The proportions of participants with a 4-fold increase in hSBA
titres one month following vaccination in the follow-on groups
ranged from 85–100% (for 5/99); 92–100% (44/76-SL); 61–88%
(NZ98/254); 31–49% (M10713) and were 90%; 73%; 27% and 24%
respectively for the vaccine-naïve group (Table 2).
3.3. Reactogenicity to vaccination at 4 years of age
The proportions of participants reporting solicited AEs are
shown in Table 2 Supplementary File. Reactogenicity was similar
across all follow-on groups. Most solicited reactions were experi-
enced within 6–24 h, a declining trend observed for all reactions
in the seven days following vaccination (Fig. 2 Supplementary File).
The most reported solicited local adverse event was transient
injection site pain, experienced by (follow on vs. vaccine-naïve)
84–100% of participants (severe in 11–32%) and 91% (severe in
13%) respectively. Most pain was experienced within the first
two days following vaccination, with 4–11% of follow-on, and 1–
6% of vaccine-naïve participants still experiencing pain seven days
post vaccination.Persistence 
Immunogenicity 
Booster 
Immunogenicity 
N=38 
N=29 N=26 [a.=3]  
N=40 [a.=1] 
N=20 N=18 [a.=1, b.=1]  
N=43 
N=17 N=16 [b.=1]  
N=47 
N=19 N=16 [a.=3] 
N=36 
N=27 N=26 [a.=1] 
N=36 [a.=1] 
N=18 N=15 [a.=2] 
N=42 [a.=1] N=41 [b.=1] 
N=28 [a.=1] N=26 [a.=2] 
N=28 N=26 [a.=1, b.=1] 
N=206 N=192 [a.=6, b.=7, e.=1] 
Codes 
a. Serological data not 
available 
b. Parcipant withdrawn 
c. No adverse event or post 
injecon data 
d. Parcipant withdrawn, 
vaccine not administered 
e. Vaccine not administered 
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398 M.A. Iro et al. / Vaccine 35 (2017) 395–402The most reported solicited systemic reaction was irritability,
reported in 47–74% of follow-on participants (severe in 2–12%)
compared with 33% (severe in 4%) for the vaccine-naïve group.
Fever rates in the follow-on group participants were 4–21% (severe
(P39 C) in 2–6%; treated in 6–25%; medically attended in 2–7%),
compared with 10% (severe in 1%; treated in 11%; medically
attended in 1%) for the vaccine-naïve group. Most fever occurred
within 6 h post vaccination and resolved by day 3–4 post vaccina-
tion for majority of participants with the exception of those in
study groups 246Con24 and 234Int12 and the vaccine-naïve group
of which 7–8%; 2% and 1–3% respectively still reported fever
between day 4 and 6 post vaccination. Fever completely resolved
by day 7 post vaccination (follow-on participants) but persisted
in 2% of the vaccine-naïve participants at this time.
SAEs observed within a month of the first vaccine were croup
and trauma. Both were judged not related to the study vaccine.
4. Discussion
This is the first study to report data on persistence of immune
responses to 4-years of age and in particular, the pattern of decline
of antibodies for the different reference strains following infant
priming and different 4CMenB boosting schedules in the second
year of life. The data show that the pattern of the decline in bacte-
ricidal antibodies 24–36 months after boosting was similar for the
different follow-on groups, suggesting that the age at priming or
boosting does not impact on antibody persistence following tod-
dler vaccination. Of note, the magnitude of this decline varied by
strain. In the absence of data reporting on the role of relatively per-
sistent bactericidal antibodies in long-term protection against
strains bearing the relevant antigens, it is unclear whether this
finding is of clinical relevance or only reflects different susceptibil-
ities of the target strains strain to killing in the SBA assay. Despite
the decline, bactericidal antibody titres at baseline in this study
(i.e. point of enrolment and prior to vaccination) were higher in
the follow-on groups than in the 4CMen B naïve group for three
of the target strains tested (5/99, 44/76-SL, NZ98/254). Even
though the target strains selected are thought to be indicative of
the immune response to NadA, fHBP and PorA, the relation
between test strain and vaccine antigen is likely to be more
nuanced due to additional antigen components in the OMV, and
a potential for cross protection between fHBP sub-variant 1.1 in
the vaccine and fHBP subvariant 1.14 in the NZ98/254 strain.
Following a dose of 4CMenB given at 4 years of age, a robust
response occurred, with consistently higher antibody titres in the
follow-on groups compared with the 4CMenB-naïve group, indi-
cating induction of immunological memory following vaccination
at earlier time points. These data provide important information
on the probable duration of protection with different vaccination
schedules, which will be informative for policymakers.
Data from this study indicate the likely need for booster doses of
4CMenB in later childhood if ongoing protection is required. While
booster vaccination in pre-school years may be justified because
the incidence of MenB disease remains high in 1 to 4–year-old chil-
dren [9], its benefit beyond pre-school years is uncertain given the
much lower risk of disease during this time. In addition, the findings
of previous studies [3,4] suggest that such a strategy is unlikely to
provide long-term protection especially to adolescence when the
next peak in disease occurs. Since the rates of MenB disease are
low after 4 years of age [9], the chief aim of an early childhood vac-
cination programme should be to achieve the best antibody
responses in the first few years of life when the burden of meningo-
coccal disease is greatest. Furthermore, in view of the variation in
epidemiology and unpredictable nature of the disease, such vacci-
nation programmes should be aligned with regional disease epi-
demiology and the timing of boosters determined by need.
Table 2
Proportion of participants (95% confidence intervals) with (i) hSBA titresP 5 for each reference strain at baseline and one month after vaccination at 4 years of age and (ii)
fourfold rise in hSBA titres after one dose of 4CMenB at 4 years.
246Con12 246Con18 246Con24 246Int12 246Int18 246Int24 234Con12 234Con18 234Con24 Naïve
Strain 5/99 (NadA)
Baseline @ 4 years 62/67 93% 59/60 98% 56/58 97% 62/64 97% 62/62 100% 54/54 100% 38/42 90% 25/28 89% 27/28 96% 9/200 5%
(83–98%) (91–100%) (88–100%) (89–100%) (94–100%) (93–100%) (77–97%) (72–98%) (82–100%) (2–8%)
One month post
booster
26/26 100% 18/18 100% 16/16 100% 16/16 100% 26/26 100% 15/15 100% 38/38 100% 26/26 100% 26/26 100% 168/188 89%
(87–100%) (81–100%) (79–100%) (79–100) (87–100%) (78–100%) (91–100%) (87–100%) (87–100%) (84–93%)
Four fold rise @
one month post
booster
25/26 96% 17/18 94% 15/16 94% 15/15 100% 23/25 92% 15/15 100% 37/38 97% 24/25 96% 22/26 85% 166/184 90%
(80–100%) (73–100%) (70–100%) (78–100%) (74–99%) (78–100%) (86–100%) (80–100%) (65–96%) (85–94%)
Strain H44/76 (fHBP)
Baseline @ 4 years 8/67 12% 11/60 18% 14/59 24% 13/65 20% 17/63 27% 19/54 35% 5/42 12% 7/28 25% 6/28 21% 1/206 0%
(5–22%) (10–30%) (14–37%) (11–32%) (17–40%) (23–49%) (4–26%) (11–45%) (8–41%) (0.01–3%)
One month post
booster
26/26 100% 18/18 100% 16/16 100% 16/16 100% 26/26 100% 15/15 100% 38/39 97% 26/26 100% 26/26 100% 135/192 70%
(87–100%) (81–100%) (79–100) (79–100%) (87–100%) (78–100%) (87–100%) (87–100%) (87–100%) (63–77%)
Four fold rise @
one month post
booster
24/26 92% 18/18 100% 16/16 100% 16/16 100% 25/26 96% 14/15 93% 38/39 97% 24/25 96% 25/26 96% 139/191 73%
(75–99%) (81–100%) (79–100%) (79–100%) (80–100%) (68–100%) (87–100%) (80–100%) (80–100%) (66–79%)
Strain NZ98/254 (OMV)
Baseline @ 4 years 6/67 9% 5/60 8% 7/60 12% 6/66 9% 7/63 11% 5/54 9% 4/42 10% 3/28 11% 3/28 11% 1/206 0%
(2–18%) (3–18%) (5–23%) (3–19%) (5–22%) (3–20%) (3–23%) (2–28%) (2–28%) (0.01–3%)
One month post
booster
24/26 92% 15/18 83% 15/16 94% 13/16 81% 23/26 88% 12/15 80% 38/40 95% 24/26 92% 24/26 92% 45/190 24%
(75–99%) (59–96%) (70–100%) (54–96%) (70–98%) (52–96%) (83–99%) (75–99%) (75–99%) (18–30%)
Four fold rise @
one month post
booster
21/26 81% 11/18 61% 13/16 81% 11/16 69% 23/26 88% 11/15 73% 35/40 88% 18/25 72% 22/26 85% 51/189 27%
(61–93%) (36–83%) (54–96%) (41–89%) (70–98%) (45–92%) (73–96%) (51–88%) (65–96%) (21–34%
Strain M10713 (NHBA)
Baseline @ 4 years 35/65 54% 40/59 68% 43/58 74% 34/62 55% 32/60 53% 43/54 80% 27/40 68% 21/28 75% 21/28 75% 116/192 60%
(41–66%) (54–79%) (61–85%) (42–68%) (40–66%) (66–89%) (51–81%) (55–89%) (55–89%) (53–67%)
One month post
booster
21/25 84% 16/18 89% 14/16 88% 13/14 93% 24/25 96% 14/15 93% 35/36 97% 25/25 100% 25/25 100% 141/186 76%
(64–95%) (65–99%) (62–98%) (66–100%) (80–100%) (68–100%) (85–100%) (86–100%) (86–100%) (70–83%)
Four fold rise @
one month post
booster
9/24 38% 8/17 47% 5/16 31% 4/12 33% 9/23 39% 6/15 40% 17/35 49% 11/24 46% 8/25 32% 42/173 24%
(19–59%) (23–72%) (11–59%) (10–65%) (20–61%) (16–68%) (31–66%) (26–67%) (15–54%) (18–31%)
M.A. Iro et al. / Vaccine 35 (2017) 395–402 399The loss of protective antibodies over time is not surprising and
has previously been described following vaccination with 4CMenB
and other meningococcal vaccines.[5,10–13] In this study, the pro-
portion of participants with protective antibodies at baseline is
similar to earlier 4CMenB phase II paediatric studies in which per-
sistence of bactericidal antibodies to 5 years following booster vac-
cination at 40 months was assessed in children who had received
either a 3+1 (2, 4, 6, 12 months) or 2+1 (6, 8, 12 months) schedule
[3,4]. The results contrast the findings in an adolescent study [14]
where the proportion of participants with protective antibodies
18–24 months following vaccination with 2 or 3 doses of 4CMenB
was much higher than observed in this study for target strains
44/76-SLand NZ98/254 but not 5/99, possibly reflecting either
immunological maturation from childhood to adolescence, priming
and boosting through pharyngeal carriage of meningococci or cross
reactive antigens in the older age group [15]. Although based on
the currently available criteria for protection, the natural decline
in circulating functional antibodies following boosting in the sec-
ond year of life might suggest that duration of protection over time
may not be guaranteed since the majority of toddlers do not have
protective antibodies against most strains, it remains unclear how
well available in vitro data match duration of protection in the
field. Additionally, the considerable inter-strain variation in the
magnitude of decline of bactericidal antibodies makes it challeng-
ing to draw any definite conclusions regarding the clinical rele-
vance of this decline, emphasising the importance of post-
implementation surveillance to obtain direct evidence of the vac-
cine’s effectiveness.
In September 2015, 4CMenB vaccine was introduced into the
UK immunisation programme in a 2+1 rather than a 3+1 schedule,
with administration of the vaccine at 2, 4 and 12 months of age.
Although this schedule has not been studied directly, data from
previous studies [4,16,17] indicate that the immunogenicity ofthe 4CMenB vaccine is not likely to be compromised by this
reduced dose vaccination schedule. In addition, since the NadA
protein is also found on the surface of the epidemic hyper-
virulent sequence type (ST) 11 meningococcal W strain which is
responsible for the recent increase in the incidence of MenW dis-
ease in the UK [18–20], the introduction of 4CMenB into the UK
immunisation programme will provide the unique opportunity to
observe the potential impact of the vaccine on capsular group W
in infants.
In this study, the safety profile of 4CMenB as a fifth dose was
also assessed and found to be generally acceptable and comparable
for the different study groups, irrespective of prime-boost schedule
received. The most reported solicited local reaction was injection
site pain, occurring in significant proportion of participants
although most were mild to moderate in nature. Rates of severe
pain were generally higher following a fifth dose of 4CMenB given
at 4 years than with a first dose given to vaccine-naïve participants
of the same age. The proportion of vaccine-naïve participants expe-
riencing severe pain with the first vaccine dose at 4 years in this
study is similar to that observed with a first dose given at 40 [3]
and 60 months [4]. In contrast, overall pain rates with a first dose
of 4CMenB at 4 years of age in this study are higher than was
observed for toddlers receiving their first vaccination at 12 or
13 months [21], possibly reflecting the ability of older children to
vocalise their symptoms. Fever rates in this study are much lower
than reported in infant studies [2,22] but comparable to those
reported in similar aged children [4] and adolescents [14], and
were mostly of mild to moderate intensity and had resolved by
day 3–4 post vaccination for the majority of the participants with
none reporting fever by day 7 post vaccination. The proportion of
participants receiving treatment for fever was low across all study
groups and <8% of participants sought medical attention for fever.
To minimise the high rates of fever observed following infant
Table 3
hSBA geometric mean titres (95% confidence interval) following a fifth dose of 4CMenB (follow on groups) compared with titres (i) after toddler booster vaccination, (ii) at
baseline at 4 years and (iii) following first dose (vaccine-naïve group).
246Con12 246Con18 246Con24 246Int12 246Int18 246Int24 234Con12 234Con18 234Con24 Naïve
Strain 5/99 (NadA)
1 month post
toddler booster
1261 2048 1599 1767 1750 2226 1526 1602 1874 –
(973–1634) (1564–2681) (1193–2145) (1392–2243) (1380–2220) (1695–2923) (1082–2151) (1054–2435) (1208–2906)
N = 61 N = 57 N = 52 N = 59 N = 56 N = 44 N = 37 N = 27 N = 25
Baseline at @
4 years
36 69 69 59 57 111 52 62 101 1.16
(27–48) (50–94) (50–96) (45–78) (43–75) (82–151) (34–81) (36–108) (57–177) (1.05–1.29)
N = 67 N = 60 N = 58 N = 64 N = 62 N = 54 N = 42 N = 28 N = 28 N = 200
One month post
booster @
4 years
766 1725 923 2006 1403 1991 1668 1227 1252 34.5
(492–1192) (1013–2936) (520–1637) (1137–3540) (900–2186) (1108–3577) (1155–2408) (783–1921) (795–1972) (27.5–43.2)
N = 26 N = 18 N = 16 N = 16 N = 26 N = 15 N = 38 N = 26 N = 26 N = 188
Strain H44/76 (fHBP)
1 month post
toddler booster
144 117 101 183 157 125 166 97 110 –
(109–188) (88–156) (74–137) (141–238) (121–205) (93–167) (119–231) (64–146) (71–170)
N = 62 N = 56 N = 53 N = 58 N = 55 N = 46 N = 38 N = 27 N = 25
Baseline at
@4 years
1.75 1.68 2.41 1.72 1.99 2.69 1.51 2.2 2.2 1.04
(1.36–2.25) (1.29–2.19) (1.83–3.19) (1.29–2.29) (1.49–2.65) (1.96–3.7) (1.04–2.18) (1.38–3.49) (1.37–3.53) (1.00–1.07)
N = 67 N = 60 N = 59 N = 65 N = 63 N = 54 N = 42 N = 28 N = 28 N = 206
One month post
booster @
4 years
109 119 112 188 193 232 159 135 120 10.3
(68–175) (67–211) (61–208) (102–346) (120–312) (123–435) (108–235) (83–219) (74–195) (8.1–13)
N = 26 N = 18 N = 16 N = 16 N = 26 N = 15 N = 39 N = 26 N = 26 N = 192
Strain NZ98/254 (OMV)
1 month post
toddler booster
45 13 20 34 17 14 46 15 26 –
(32–62) (9.31–19) (14–29) (24–47) (12–24) (9.32–20) (30–71) (8.89–26) (15–46)
N = 63 N = 57 N = 54 N = 59 N = 56 N = 47 N = 39 N = 28 N = 25
Baseline at
@4 years
1.25 1.29 1.38 1.48 1.34 1.52 1.32 1.25 1.62 1.01
(1.03–1.52) (1.05–1.59) (1.11–1.72) (1.2–1.83) (1.08–1.66) (1.2–1.92) (1.05–1.65) (0.94–1.66) (1.21–2.16) (0.98–1.03)
N = 67 N = 60 N = 60 N = 66 N = 63 N = 54 N = 42 N = 28 N = 28 N = 206
One month post
booster @
4 years
21 11 30 16 21 16 26 18 26 2.24
(13–34) (6–19) (16–55) (9–30) (13–34) (9–30) (18–38) (11–28) (16–42) (1.82–2.74)
N = 26 N = 18 N = 16 N = 16 N = 26 N = 15 N = 40 N = 26 N = 26 N = 190
Strain M10713 (NHBA)
1 month post
toddler booster
– – – – – – 14 13 23 –
(8.75–23) (7.55–23) (13–40)
N = 27 N = 24 N = 25
Baseline at 4 years 6.14 7.36 9.08 7.86 7.77 15 9.61 11 11 8.0
(4.19–8.99) (4.94–11) (5.97–14) (5.17–12) (5.07–12) (9.49–24) (5.81–16) (5.92–20) (5.9–21) (6.04–10.6)
N = 65 N = 59 N = 58 N = 62 N = 60 N = 54 N = 40 N = 28 N = 28 N = 192
One month post
booster @
4 years
22 21 31 37 38 36 51 51 44 18
(14–35) (12–35) (17–55) (20–69) (24–60) (20–66) (35–75) (32–81) (27–70) (14–24)
N = 25 N = 18 N = 16 N = 14 N = 25 N = 15 N = 36 N = 25 N = 25 N = 186
400 M.A. Iro et al. / Vaccine 35 (2017) 395–402immunisation, the recommendation in the UK is for paracetamol to
be routinely given at the time of immunisation with 4CMenB at 2
and 4 (but not 12) months, and two further doses to given at 4–6
hourly intervals [23]. Given the low rates of fever in this study,
the use of paracetamol for this purpose is unlikely to be a require-
ment for immunisation at 4 years of age.
The geographical spread of the study population makes the data
presented here more generalisable across different populations
than previously published similar studies. Inclusion of a control
group of robust sample size makes it possible to compare the post
boost immunogenicity of the different schedules with that induced
following a first dose administered to vaccine-naïve children at
4 years of age and strengthens interpretation of the data. Although
the numbers in each study group were small, these exceed those in
previously published studies.5. Conclusion
These data demonstrate that 4CMenB induced immunological
memory when administered using different infant vaccination
schedules and is immunogenic in vaccine-naïve 4-year-old chil-
dren, but antibody levels wane after administration of a booster
dose to toddlers. The introduction of 4CMenB in the UK represents
an important milestone in the prevention of childhood meningitis
and septicaemia. Data from the impact evaluation will allow effec-tiveness to be aligned with these data on antibody persistence and
waning and will inform future policy decisions.
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